Citation Tools
PDFRegular and Young Investigator Award Abstracts
Clinical Trial In Progress
753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors